MPZL2 CRISPR Activation Plasmid (m): sc-420242-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MPZL2 CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- MPZL2 CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by MPZL2 CRISPR Activation Plasmid (m) and MPZL2 CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Mpzl2 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MPZL2 CRISPR Activation Plasmid (m) | sc-420242-ACT | 20 µg | $397.00 |
Mouse Mpzl2 encodes MPZL2, an immunoglobulin superfamily transmembrane protein implicated in cell–cell adhesion and epithelial barrier organization. MPZL2 has been linked to receptor-associated signaling networks that influence cytoskeletal dynamics, contact-dependent growth control, and tissue architecture, with downstream effects on proliferation and differentiation programs. In murine systems, altered MPZL2 activity is used to probe mechanisms of epithelial homeostasis and stress responses, including pathways relevant to inflammation-associated remodeling and neoplastic transformation. Mpzl2 expression modulation therefore provides a tractable entry point for studying adhesion-dependent signaling and microenvironmental regulation in vivo and in cultured cells.
MPZL2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Mpzl2 expression without altering the underlying DNA sequence.
MPZL2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Mpzl2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Mpzl2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous MPZL2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Mpzl2 locus and enabling the study of MPZL2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of MPZL2 pathway restoration in tumor cells with silenced or reduced Mpzl2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.